行情

SLS

SLS

Galena生物制药
NASDAQ

实时行情|Nasdaq Last Sale

0.1259
-0.0027
-2.10%
盘前: 0.1260 +0.0001 +0.08% 07:33 10/18 EDT
开盘
0.1282
昨收
0.1286
最高
0.1282
最低
0.1245
成交量
357.64万
成交额
--
52周最高
2.460
52周最低
0.1021
市值
2,852.20万
市盈率(TTM)
-0.0842
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SLS 新闻

  • 中通快递将于11月19日发布2019年第三季度财报
  • 新浪科技.57分钟前
  • 土耳其同意在叙利亚暂时停火,美元持续回落
  • 汇通网.1小时前
  • “美元微笑”已减弱 不再是新兴市场交易员避风港
  • 环球外汇网官网.1小时前
  • "超级周六"投票约翰逊孤注一掷 脱欧之路仍坎坷不定
  • 新浪美股.1小时前

更多

所属板块

制药
+0.54%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

SLS 简况

SELLAS Life Sciences Group, Inc., formerly Galena Biopharma, Inc., is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system.
展开

Webull提供Sellas Life Sciences Group Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。